6850-22-2

Basic information

• Product Name: 5-23-06-00185 (Beilstein Handbook Reference)
• Synonyms: 5-23-06-00185 (Beilstein Handbook Reference);6-Nitro-2-methyl-2H-indazole;NSC 131653;2-methyl-6-nitro-2H-indazole, 2-methyl-6-nitroindazole, 2-methyl-6-nitro-2H-indazole, 2-Methyl-6-nitro-2H-indazol, 2-methyl-6-nitro-indazole, 2-Methyl-6-nitro-indazol, 2-Methyl-6-nitroindazol
• CAS NO: 6850-22-2
• Molecular Formula: C₈H₇N₃O₂
• Molecular Weight: 177.16
• Mol File: 6850-22-2.mol
• Article Data: 15

Chemical Properties

• Melting Point: 158 °C
• Boiling Point: 364.5°Cat760mmHg
• Flash Point: 174.2°C
• Appearance: /
• Density: 1.42g/cm³
• Vapor Pressure: 3.51E-05mmHg at 25°C
• Refractive Index: 1.676
• Storage Temp.: 2-8°C
• PKA: -1.81±0.30(Predicted)
• CAS DataBase Reference: 5-23-06-00185 (Beilstein Handbook Reference)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-23-06-00185 (Beilstein Handbook Reference)(6850-22-2)
• EPA Substance Registry System: 5-23-06-00185 (Beilstein Handbook Reference)(6850-22-2)

Safety Data

• Hazardous Substances Data: 6850-22-2(Hazardous Substances Data)

Usage

Description

5-23-06-00185 (Beilstein Handbook Reference) is a unique identifier for a chemical compound within the Beilstein Handbook of Organic Chemistry. The specific chemical composition and properties of this compound are not provided in the summary, but the reference number allows for easy access to more detailed information in the Beilstein Handbook, a comprehensive manual of organic compounds and their properties.

Uses

Since the specific chemical composition and properties of 5-23-06-00185 are not provided in the summary, it is not possible to list its uses based on the given materials. However, the reference number can be used to look up the compound in the Beilstein Handbook to find information about its applications and potential uses in various industries.

InChI:InChI=1/C8H7N3O2/c1-10-5-6-2-3-7(11(12)13)4-8(6)9-10/h2-5H,1H3

Upstream product

• 95-53-4 o-toluidine 
• 616-38-6 carbonic acid dimethyl ester 
• 7597-18-4 6-nitroindazole 
• 74-88-4 methyl iodide 
• 2533-69-9 methyl 2,2,2-trichloroacetimidate 
• 99-55-8 2-methyl-5-nitroaniline 
• 420-37-1 trimethoxonium tetrafluoroborate 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 50593-30-1 2-methyl-2H-indazol-6-amine 
• 1311986-73-8 N²-(3-fluorophenyl)-N⁴-methyl-N⁴-(2-methyl-2H-indazol-6-yl)pyrimidine-2,4-diamine 
• 1311986-77-2 N²-(3-chlorophenyl)-N⁴-methyl-N⁴-(2-methyl-2H-indazol-6-yl)pyrimidine-2,4-diamine 
• 1311986-75-0 N²-(3-methoxyphenyl)-N⁴-methyl-N⁴-(2-methyl-2H-indazol-6-yl)pyrimidine-2,4-diamine 
• 1311986-81-8 N⁴-methyl-N⁴-(2-methyl-2H-indazol-6-yl)-N²-(4-(trifluoromethoxy)phenyl)pyrimidine-2,4-diamine 
• 1311986-79-4 N²-(3,5-dimethylphenyl)-N⁴-methyl-N⁴-(2-methyl-2H-indazol-6-yl)pyrimidine-2,4-diamine 
• 1620059-17-7 5-[[4-[N-(2-methyl-2H-indazol-6-yl)-N-methylamino]-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide 
• 132283-43-3 2-(2-Methyl-2H-indazol-6-ylamino)-benzoic acid 
• 52470-67-4 2-methyl-6-hydroxyindazole 
• 74209-41-9 3-bromo-2-methyl-6-nitro-2H-indazole 

Relevant articles and documents

Design, synthesis and bioevaluation of novel 6-substituted aminoindazole derivatives as anticancer agents

In the present study, a series of 6-substituted aminoindazole derivatives were designed, synthesized, and evaluated for bio-activities. The compounds were initially designed as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors based on the structural feature of five IDO1 inhibitors, which are currently on clinical trials, and the important anticancer activity of the indazole scaffold. One of them, compound N-(4-fluorobenzyl)-1,3-dimethyl-1H-indazol-6-amine (36), exhibited a potent anti-proliferative activity with an IC50 value of 0.4 ± 0.3 μM in human colorectal cancer cells (HCT116). This compound also remarkably suppressed the IDO1 protein expression. In the cell-cycle studies, the suppressive activity of compound 36 in HCT116 cells was related to the G2/M cell cycle arrest. Altogether, the current findings demonstrate that compound 36 would be promising for further development as a potential anticancer agent.

One-pot synthesis of new 6-pyrrolyl-N-alkyl-indazoles from reductive coupling of N-alkyl-6-nitroindazoles and 2,5-hexadione

One-pot synthesis of 6-pyrrolyl-N-alkyl-indazoles by the reductive coupling of N-alkyl-6-nitroindazoles and 2,5-hexadione was investigated in the presence of different reducing agents (SnCl2/AcOH and In/AcOH in THF). Indazoles 5a-h and 6a-h wer

Discovery and synthesis of N2,N4-substitued- cycloalkyl[d]pyrimidine-2,4-diamine analogs: The first examples of small-molecular FGFR-1 activator

A series of novel, cycloalkyl-modified pazopanib analogs 2 and 3 were designed and synthesized. Their kinase modulatory effects on FGFR-1, VEGFR-2, PDGFR-β, and c-KIT were evaluated by the caliper mobility shift assay. Introduction of cycloalkyl into the pyrimidine linker of pazopanib almost abolished the four kinases inhibitory potency of compounds 2 and 3, but surprisingly, resulted in good activation effects on FGFR-1. Compounds 3d and 3g showed double-digit, nanomolar, selective activation effects on FGFR-1, and could be classified as first-generation small molecular activators of FGFR-1 kinase.